CEP Biomarkers as Potential Tools for Monitoring Therapeutics

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Renganathan, Kutralanathan ^a,b   Gu, Jiayin ^a,b   Rayborn, Mary E ^a   Crabb, John S ^a   Salomon, Robert G ^b   Collier, Robert J ^c   Kapin, Michael A ^c   Romano, Carmelo ^c   Hollyfield, Joe G ^a,d   Crabb, John W ^a,c,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AL 8309A; AUTOANTIBODY; BIOLOGICAL MARKER; CARBOXYETHYLPYRROLE; PYRROLE DERIVATIVE; SEROTONIN 1A AGONIST; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VIVO STUDY; LIGHT EXPOSURE; MALE; NONHUMAN; PHOTOOXIDATION; RAT; RETINA MACULA AGE RELATED DEGENERATION; TISSUE LEVEL; TREATMENT OUTCOME; WESTERN BLOTTING;

ANIMALS; AUTOANTIBODIES; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; LIGHT; MACULAR DEGENERATION; MALE; OXIDATION-REDUCTION; PYRROLES; RATS; RETINA;

EID: 84885073554     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076325     Document Type: Article

References (56)

1. Jager RD, Mieler WF, Miller JW, (2008) Age-related macular degeneration. N Engl J Med 358: 2606-2617. doi:10.1056/NEJMra0801537. PubMed: 18550876.
2. Ding X, Patel M, Chan CC, (2009) Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 28: 1-18. doi:10.1016/j.preteyeres.2008.10.001. PubMed: 19026761.
3. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, et al. (2010) The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited. Prog Retin Eye Res 29: 95-112. doi:10.1016/j.preteyeres.2009.11.003. PubMed: 19961953.
4. Crabb JW, (2012) Oxidative Modifications as Triggers of AMD Pathology. In: Stratton R, Hauswirth W, Gardiner T, eds. Oxidative Stress in Applied Basic Research and Clinical Practice: Studies in Retinal and Choroidal Disorders. New York: Humana Press. pp. pp. 65-84.
5. Crabb JW, Miyagi M, Gu X, Shadrach K, West KA, et al. (2002) Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A 99: 14682-14687. doi:10.1073/pnas.222551899. PubMed: 12391305.
6. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, et al. (2001) An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 20: 705-732. doi:10.1016/S1350-9462(01)00010-6. PubMed: 11587915.
7. Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH, (2000) A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res 70: 441-449. doi:10.1006/exer.1999.0798. PubMed: 10865992.
8. Edwards AO, Ritter, Rr, Abel K, Manning A, Panhuysen C,et al (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308: 421-424. doi:10.1126/science.1110189. PubMed: 15761121.
9. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, et al. (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 102: 7227-7232. doi:10.1073/pnas.0501536102. PubMed: 15870199.
10. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, et al. (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science 308: 419-421. doi:10.1126/science.1110359. PubMed: 15761120.
11. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, et al. (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308: 385-389. doi:10.1126/science.1109557. PubMed: 15761122.
12. Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, et al. (2006) Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 38: 458-462. doi:10.1038/ng1750. PubMed: 16518403.
13. Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, et al. (2007) Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 357: 553-561. doi:10.1056/NEJMoa072618. PubMed: 17634448.
14. Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, et al. (2007) Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet 39: 1200-1201. doi:10.1038/ng2131. PubMed: 17767156.
15. Yuan X, Gu X, Crabb JS, Yue X, Shadrach K, et al. (2010) Quantitative proteomics: comparison of the macular Bruch membrane/choroid complex from age-related macular degeneration and normal eyes. Mol Cell Proteomics 9: 1031-1046. doi:10.1074/mcp.M900523-MCP200. PubMed: 20177130.
16. Eye Age-Related, Disease Study Group (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119: 1417-1436.
17. Seddon JM, Willett WC, Speizer FE, Hankinson SE, (1996) A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 276: 1141-1146. doi:10.1001/jama.276.14.1141. PubMed: 8827966.
18. Ebrahem Q, Renganathan K, Sears J, Vasanji A, Gu X, et al. (2006) Carboxyethylpyrrole oxidative protein modifications stimulate neovascularization: Implications for age-related macular degeneration. Proc Natl Acad Sci U S A 103: 13480-13484. doi:10.1073/pnas.0601552103. PubMed: 16938854.
19. West XZ, Malinin NL, Merkulova AA, Tischenko M, Kerr BA, et al. (2010) Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467: 972-976. doi:10.1038/nature09421. PubMed: 20927103.
20. Hollyfield JG, Bonilha VL, Rayborn ME, Yang X, Shadrach KG, et al. (2008) Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med 14: 194-198. doi:10.1038/nm1709. PubMed: 18223656.
21. Gu X, Meer SG, Miyagi M, Rayborn ME, Hollyfield JG, et al. (2003) Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem 278: 42027-42035. doi:10.1074/jbc.M305460200. PubMed: 12923198.
22. Gu J, Pauer GJ, Yue X, Narendra U, Sturgill GM, et al. (2009) Assessing susceptibility to age-related macular degeneration with proteomic and genomic biomarkers. Mol Cell Proteomics 8: 1338-1349. doi:10.1074/mcp.M800453-MCP200. PubMed: 19202148.
23. Justilien V, Pang JJ, Renganathan K, Zhan X, Crabb JW, et al. (2007) SOD2 Knockdown Mouse Model of Early AMD. Invest Ophthalmol Vis Sci 48: 4407-4420. doi:10.1167/iovs.07-0432. PubMed: 17898259.
24. Organisciak D, Wong P, Rapp C, Darrow R, Ziesel A, et al. (2012) Light-induced retinal degeneration is prevented by zinc, a component in the age-related eye disease study formulation. Photochem Photobiol 88: 1396-1407. doi:10.1111/j.1751-1097.2012.01134.x. PubMed: 22385127.
25. Collier RJ, Patel Y, Martin EA, Dembinska O, Hellberg M, et al. (2010) Agonists at the Serotonin Receptor (5HT1A) Protect the Retina from Severe Photo-Oxidative Stress. Invest Ophthalmol Vis Sci 52: 2118-2126.
26. Collier RJ, Wang Y, Smith SS, Martin E, Ornberg R, et al. (2011) Complement Deposition and Microglial Activation in the Outer Retina in Light-Induced Retinopathy: Inhibition by a 5-HT1A agonist. Invest Ophthalmol Vis Sci 52: 8108-8116. doi:10.1167/iovs.10-6418. PubMed: 21467172.
27. Delmelle M, Noell WK, Organisciak DT, (1975) Hereditary retinal dystrophy in the rat: rhodopsin, retinol, vitamin A deficiency. Exp Eye Res 21: 369-380. doi:10.1016/0014-4835(75)90047-0. PubMed: 1218544.
28. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685. doi:10.1038/227680a0. PubMed: 5432063.
29. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254. doi:10.1016/0003-2697(76)90527-3. PubMed: 942051.
30. Nakata K, Crabb JW, Hollyfield JG, (2005) Crystallin distribution in Bruch's membrane-choroid complex from AMD and age-matched donor eyes. Exp Eye Res 80: 821-826. doi:10.1016/j.exer.2004.12.011. PubMed: 15939038.
31. Bando H, Shadrach KG, Rayborn ME, Crabb JW, Hollyfield JG, (2007) Clathrin and adaptin accumulation in drusen, Bruch's membrane and choroid in AMD and non-AMD donor eyes. Exp Eye Res 84: 135-142. doi:10.1016/j.exer.2006.09.008. PubMed: 17097084.
32. Welinder C, Ekblad L, (2011) Coomassie staining as loading control in Western blot analysis. J Proteome Res 10: 1416-1419. doi:10.1021/pr1011476. PubMed: 21186791.
33. Miyagi M, Sakaguchi H, Darrow RM, Yan L, West KA, et al. (2002) Evidence that light modulates protein nitration in rat retina. Mol Cell Proteomics 1: 293-303. doi:10.1074/mcp.M100034-MCP200. PubMed: 12096111.
34. Dixon WJ, (1953) Processing Data for Outliers. Biometrics 9: 74-89. doi:10.2307/3001634.
35. Rorabacher DB, (1991) Statistical treatment for rejection of deviant values: critical values of Dixon's "Q" parameter and related subrange ratios at the 95% confidence level. Anal Chem 63: 139-146. doi:10.1021/ac00003a730.
36. R-Development-Team (2008) R: a language and environment for statistical computing. In: Computing RFfS, editor Vienna, Austria.
37. Shapiro SS, Wilk MB, (1965) An analysis of variance test for normality (complete samples). Biometrika 52: 591-611. doi:10.1093/biomet/52.3-4.591.
38. Gu X, Sun M, Gugiu B, Hazen S, Crabb JW, et al. (2003) Oxidatively truncated docosahexaenoate phospholipids: total synthesis, generation, and peptide adduction chemistry. J Org Chem 68: 3749-3761. doi:10.1021/jo026721t. PubMed: 12737551.
39. Fliesler SJ, Anderson RE, (1983) Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res 22: 79-131. doi:10.1016/0163-7827(83)90004-8. PubMed: 6348799.
40. Alvarez RA, Aguirre GD, Acland GM, Anderson RE, (1994) Docosapentaenoic acid is converted to docosahexaenoic acid in the retinas of normal and prcd-affected miniature poodle dogs. Invest Ophthalmol Vis Sci 35: 402-408. PubMed: 8112987.
41. Wang N, Anderson RE, (1992) Enrichment of polyunsaturated fatty acids from rat retinal pigment epithelium to rod outer segments. Curr Eye Res 11: 783-791. doi:10.3109/02713689209000751. PubMed: 1424722.
42. Baradell LB, Fitton A, (1996) Tandospirone. CNS Drugs 5.
43. Fulton B, Brogden RN, (1997) Buspirone. CNS Drugs 7: 68-88. doi:10.2165/00023210-199707010-00007.
44. Mauler F, Horváth E, (2005) Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury. J Cereb Blood Flow Metab 25: 451-459. doi:10.1038/sj.jcbfm.9591524.0451. PubMed: 15674237.
45. Ramos AJ, Rubio MD, Defagot C, Hischberg L, Villar MJ, et al. (2004) The 5HT1A receptor agonist, 8-OH-DPAT, protects neurons and reduces astroglial reaction after ischemic damage caused by cortical devascularization. Brain Res 1030: 201-220. doi:10.1016/j.brainres.2004.10.019. PubMed: 15571670.
46. Alessandri B, Tsuchida E, Bullock RM, (1999) The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat. Brain Res 845: 232-235. doi:10.1016/S0006-8993(99)01948-4. PubMed: 10536203.
47. Kline AE, Yu J, Massucci JL, Zafonte RD, Dixon CE, (2002) Protective effects of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin against traumatic brain injury-induced cognitive deficits and neuropathology in adult male rats. Neurosci Lett 333: 179-182. doi:10.1016/S0304-3940(02)01101-1. PubMed: 12429377.
48. Oosterink BJ, Harkany T, Luiten PG, (2003) Post-lesion administration of 5-HT1A receptor agonist 8-OH-DPAT protects cholinergic nucleus basalis neurons against NMDA excitotoxicity. Neuroreport 14: 57-60. doi:10.1097/00001756-200301200-00011. PubMed: 12544831.
49. Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A, (2005) Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res 1043: 32-41. doi:10.1016/j.brainres.2005.02.072. PubMed: 15862515.
50. Adayev T, Ray I, Sondhi R, Sobocki T, Banerjee P, (2003) The G protein-coupled 5-HT1A receptor causes suppression of caspase-3 through MAPK and protein kinase Calpha. Biochim Biophys Acta 1640: 85-96. doi:10.1016/S0167-4889(03)00023-5. PubMed: 12676358.
51. Cowen DS, Molinoff PB, Manning DR, (1997) 5-hydroxytryptamine1A receptor-mediated increases in receptor expression and activation of nuclear factor-kappaB in transfected Chinese hamster ovary cells. Mol Pharmacol 52: 221-226. PubMed: 9271344.
52. Guo Z, Boekhoudt GH, Boss JM, (2003) Role of the intronic enhancer in tumor necrosis factor-mediated induction of manganous superoxide dismutase. J Biol Chem 278: 23570-23578. doi:10.1074/jbc.M303431200. PubMed: 12684509.
53. Rojo AI, Salinas M, Martín D, Perona R, Cuadrado A, (2004) Regulation of Cu/Zn-superoxide dismutase expression via the phosphatidylinositol 3 kinase/Akt pathway and nuclear factor-kappaB. J Neurosci 24: 7324-7334. doi:10.1523/JNEUROSCI.2111-04.2004. PubMed: 15317858.
54. Kucharczak J, Simmons MJ, Fan Y, Gélinas C, (2003) To be, or not to be: NF-kappaB is the answer--role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 22: 8961-8982. doi:10.1038/sj.onc.1207230. PubMed: 14663476.
55. Druse MJ, Tajuddin NF, Gillespie RA, Le P, (2006) The effects of ethanol and the serotonin(1A) agonist ipsapirone on the expression of the serotonin(1A) receptor and several antiapoptotic proteins in fetal rhombencephalic neurons. Brain Res 1092: 79-86. doi:10.1016/j.brainres.2006.02.065. PubMed: 16687129.
56. Marc RE, Jones BW, Watt CB, Vazquez-Chona F, Vaughan DK, et al. (2008) Extreme retinal remodeling triggered by light damage: implications for age related macular degeneration. Mol Vis 14: 782-806. PubMed: 18483561.